JP4646806B2 - 組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン - Google Patents

組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン Download PDF

Info

Publication number
JP4646806B2
JP4646806B2 JP2005512815A JP2005512815A JP4646806B2 JP 4646806 B2 JP4646806 B2 JP 4646806B2 JP 2005512815 A JP2005512815 A JP 2005512815A JP 2005512815 A JP2005512815 A JP 2005512815A JP 4646806 B2 JP4646806 B2 JP 4646806B2
Authority
JP
Japan
Prior art keywords
clpp
clpl
heat shock
protein
pneumococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2005512815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007528839A (ja
Inventor
リー，ドン−クウォン
クウォン，ヒョク−ヤン
チョイ，ミュ−ヒョン
オグンイユィ，アビオダン・デーヴィッド
パトン，ジェームズ・クレランド
Original Assignee
スンギュンカン ユニバーシティ
アデレード リサーチ アンド イノベーション ピーティーワイ エルティーディー（エイアールアイ）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スンギュンカン ユニバーシティ, アデレード リサーチ アンド イノベーション ピーティーワイ エルティーディー（エイアールアイ） filed Critical スンギュンカン ユニバーシティ
Publication of JP2007528839A publication Critical patent/JP2007528839A/ja
Application granted granted Critical
Publication of JP4646806B2 publication Critical patent/JP4646806B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2005512815A 2003-12-31 2003-12-31 組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン Expired - Lifetime JP4646806B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2003/002929 WO2005063283A1 (en) 2003-12-31 2003-12-31 Vaccine comprising recombinant clpp protein of streptococcus pneumoniae

Publications (2)

Publication Number Publication Date
JP2007528839A JP2007528839A (ja) 2007-10-18
JP4646806B2 true JP4646806B2 (ja) 2011-03-09

Family

ID=34737821

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005512815A Expired - Lifetime JP4646806B2 (ja) 2003-12-31 2003-12-31 組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン
JP2004350668A Pending JP2005194264A (ja) 2003-12-31 2004-12-03 組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004350668A Pending JP2005194264A (ja) 2003-12-31 2004-12-03 組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン

Country Status (4)

Country Link
US (1) US20080292662A1 (enExample)
JP (2) JP4646806B2 (enExample)
AU (1) AU2003288788B2 (enExample)
WO (1) WO2005063283A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2910647A1 (en) 2008-12-30 2015-08-26 Gen-Probe Incorporated Compositions, kits and related methods for the detection and/or monitoring of listeria
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US10702596B2 (en) * 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685943B1 (en) * 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
CA2315880A1 (en) * 1997-12-31 1999-07-15 Stressgen Biotechnologies Corporation Streptococcal heat shock proteins of the hsp60 family

Also Published As

Publication number Publication date
WO2005063283A1 (en) 2005-07-14
JP2005194264A (ja) 2005-07-21
AU2003288788B2 (en) 2007-02-15
AU2003288788A1 (en) 2005-07-21
JP2007528839A (ja) 2007-10-18
US20080292662A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
Lukomski et al. Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains.
US8728490B2 (en) Streptococcus suis vaccines and diagnostic tests
Goebel et al. Bacterial hemolysins as virulence factors
Cao et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP
JP2017074071A (ja) 分類不能型インフルエンザ菌の中耳炎単離物の遺伝子
KR20010104693A (ko) 신규한 스트렙토코커스 항원
JP2002521058A (ja) 肺炎連鎖球菌由来の核酸及びタンパク質
Hamilton et al. Mutation of the maturase lipoprotein attenuates the virulence of Streptococcus equi to a greater extent than does loss of general lipoprotein lipidation
KR102071743B1 (ko) 신규의 약독화된 시겔라 생백신
CN110582296B (zh) 通过减弱细菌叶酸转运来减弱细菌毒力
EA023702B1 (ru) СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ STREPTOCOCCUS PNEUMONIA И ПРИМЕНЕНИЕ БЕЛКА PhtX
JP4646806B2 (ja) 組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン
WO2012009774A2 (pt) Microrganismos recombinantes, métodos de preparação de linhagens vacinais, antígenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
CN1703238B (zh) 重组细胞内病原体免疫原组合物及其使用方法
US8828409B2 (en) Vaccine comprising recombinant CLPP protein of Streptococcus pneumoniae
EP2256185B1 (en) Heterologous protection against pasteurella multocida provided by p. multocida fur cells and the outer-membrane protein extracts thereof
JP2006501304A5 (enExample)
KR100814616B1 (ko) 재조합 폐렴구균 ClpP 단백질을 포함하는 백신
KR20050071323A (ko) 재조합 폐렴구균 ClpP 단백질을 포함하는 백신
JP7671772B2 (ja) 糖鎖改変細菌を含むワクチン
US20170173139A1 (en) Vaccine
Li et al. stringent response pathway, facilitated by genomic diversity
Neal-McKinney Elucidation of Campylobacter pathogenesis in humans and commensal colonization in chickens

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101108

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101207

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131217

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4646806

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term